What is he best known for?
The fields of study he is best known for:
- DNA
- Gene
- Internal medicine
Michael D. Miller mainly focuses on Virology, Internal medicine, Reverse transcriptase, Immunology and Hepatitis B virus.
All of his Virology and Viral replication, Lamivudine, Reverse-transcriptase inhibitor, Lentivirus and Virus investigations are sub-components of the entire Virology study.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Raltegravir.
Michael D. Miller combines subjects such as Integrase and Viral load with his study of Raltegravir.
His Reverse transcriptase research incorporates elements of Molecular biology and Polymerase, DNA.
His studies examine the connections between Immunology and genetics, as well as such issues in Pharmacotherapy, with regards to Antiretroviral treatment, Prospective cohort study and Retrospective cohort study.
His most cited work include:
- Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. (1233 citations)
- Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells (972 citations)
- Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. (713 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Virology, Reverse transcriptase, Internal medicine, Virus and Reverse-transcriptase inhibitor.
His Virology research includes themes of Resistance mutation, Drug resistance and Genotype.
The Drug resistance study which covers Integrase that intersects with Raltegravir Potassium.
The Reverse transcriptase study combines topics in areas such as Mutation, Mutant, Molecular biology, Viral replication and Lentivirus.
His studies in Internal medicine integrate themes in fields like Gastroenterology, Viral load and Oncology.
Michael D. Miller has researched Reverse-transcriptase inhibitor in several fields, including Zidovudine and Nucleotidyltransferase.
He most often published in these fields:
- Virology (60.13%)
- Reverse transcriptase (22.88%)
- Internal medicine (17.97%)
What were the highlights of his more recent work (between 2012-2018)?
- Virology (60.13%)
- Genotype (15.03%)
- Drug resistance (15.03%)
In recent papers he was focusing on the following fields of study:
Michael D. Miller spends much of his time researching Virology, Genotype, Drug resistance, Emtricitabine and Internal medicine.
Virology is closely attributed to Elvitegravir in his research.
His Drug resistance study incorporates themes from Hepatitis B, Lamivudine, Hepatitis B virus and Reverse transcriptase.
As part of the same scientific family, he usually focuses on Reverse transcriptase, concentrating on Molecular biology and intersecting with Cell and In vitro.
His Emtricitabine research is multidisciplinary, incorporating elements of Tenofovir alafenamide, Regimen, Efavirenz, Resistance mutation and Pharmacology.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology, Viremia and Viral load.
Between 2012 and 2018, his most popular works were:
- Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs (238 citations)
- No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B (177 citations)
- A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals (159 citations)
In his most recent research, the most cited papers focused on:
- DNA
- Gene
- Internal medicine
The scientist’s investigation covers issues in Virology, Hepatitis C virus, Sofosbuvir, Genotype and Drug resistance.
His study in Virus, Ribavirin, NS5A, Reverse-transcriptase inhibitor and Viral replication is carried out as part of his studies in Virology.
His biological study spans a wide range of topics, including NS5B, Gastroenterology, Internal medicine, Hepatitis C and Ledipasvir.
His studies deal with areas such as Regimen and Clinical trial as well as Genotype.
His work deals with themes such as Hepatitis B virus and Emtricitabine, which intersect with Drug resistance.
His research in Emtricitabine intersects with topics in Hepatitis B and Adefovir.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
